Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 1:44 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Disease Management Clear all
Recruiting Phase 2 Interventional

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC)

NCT06979336
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
RO7837195, RO7837195 Matched Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
8
States / cities
Lancaster, California • San Diego, California • Colorado Springs, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Sep 23, 2026, 1:44 PM EDT
Completed Early Phase 1 Interventional

Value of Ondansetron Medication vs Inhaled Isopropyl Therapy in the Emergency Department (VOMIITED)

NCT03125811
View directory record Official record
Conditions
Nausea, Vomiting
Interventions
Inhaled Isopropyl Alcohol (IPA), Oral Dissolvable Tablet Zofran (ondansetron)
Other · Drug
Lead sponsor
Texas Tech University Health Sciences Center, El Paso
Other
Eligibility
18 Years to 65 Years
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
2
States / cities
El Paso, Texas
Source: ClinicalTrials.gov public record
Updated Aug 28, 2023 · Synced Sep 23, 2026, 1:44 PM EDT
Active, not recruiting Not applicable Interventional

Exposure Therapy Study In Adults With Eating Disorders

NCT06171711
View directory record Official record
Conditions
Eating Disorders, Anorexia Nervosa
Interventions
Exposure Therapy
Behavioral
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
17 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Sep 23, 2026, 1:44 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo

NCT01576471
View directory record Official record
Conditions
Crohn's Disease
Interventions
Trichuris suis ova (TSO), Placebo
Biological
Lead sponsor
Coronado Biosciences, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
73
States / cities
Tucson, Arizona • Little Rock, Arkansas • Anaheim, California + 64 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2017 · Synced Sep 23, 2026, 1:44 PM EDT
Available No phase listed Expanded access

NRX-101 Expanded Access

NCT05779267
View directory record Official record
Conditions
Treatment-Resistant Depression
Interventions
NRX-101, Transcranial Magnetic Stimulation Sham
Drug · Device
Lead sponsor
NeuroRx, Inc.
Industry
Eligibility
18 Years and older
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Sep 23, 2026, 1:44 PM EDT
Completed Phase 4 Interventional

A Phase 4, Conversion Study of Hectorol® Injection to Hectorol® Capsules in Stage 5 CKD Patients on Dialysis

NCT00418600
View directory record Official record
Conditions
Secondary Hyperparathyroidism
Interventions
Hectorol® (doxercalciferol capsules), doxercalciferol capsules, Hectorol®, doxercalciferol capsules, Hectorol® capsules
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
8
States / cities
Hot Springs, Arkansas • Downey, California • Tarzana, California + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2015 · Synced Sep 23, 2026, 1:44 PM EDT
Completed Phase 1 Interventional

Dose Escalation of Hypofractionated Radiation Therapy in Patients With Metastatic Cancer

NCT01215500
View directory record Official record
Conditions
Tumor, Cancer, Melanoma, Sarcoma, Carcinoma
Interventions
Hypofractionated RT
Radiation
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2018
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 11, 2018 · Synced Sep 23, 2026, 1:44 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Maladaptive Anger Treatment

NCT06275607
View directory record Official record
Conditions
Anger, Intermittent Explosive Disorder, Emotional Distress, Aggression, Violence
Interventions
Cognitive Behavioral Affective Therapy, Emotional Discussion
Behavioral
Lead sponsor
The University of Texas at San Antonio
Other
Eligibility
18 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 22, 2024 · Synced Sep 23, 2026, 1:44 PM EDT
Completed Not applicable Interventional

Treatment of Low Metabolic Rate Following Bariatric Surgery

NCT01596907
View directory record Official record
Conditions
Morbid Obesity
Interventions
Ephedrine sulfate with caffeine, cellulose
Drug
Lead sponsor
Oregon Weight Loss Surgery, LLC
Other
Eligibility
18 Years to 70 Years
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
2
States / cities
Beaverton, Oregon • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 23, 2015 · Synced Sep 23, 2026, 1:44 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate ALKS 5461 in Subjects With Major Depressive Disorder (MDD)

NCT01500200
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
ALKS 5461, Placebo
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
27
States / cities
Tucson, Arizona • Oceanside, California • Santa Ana, California + 24 more
Source: ClinicalTrials.gov public record
Updated May 20, 2019 · Synced Sep 23, 2026, 1:44 PM EDT
Completed Phase 2 Interventional

Toronto and Oak Ridge Photobiomodulation Study for Dry Age Related Macular Degeneration

NCT00940407
View directory record Official record
Conditions
Nonexudative Age-related Macular Degeneration
Interventions
Photobiomodulation (Gentlewaves, Warp 10)
Device
Lead sponsor
Merry, Graham, M.D.
Individual
Eligibility
50 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Oak Ridge, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 17, 2011 · Synced Sep 23, 2026, 1:44 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Testing Afatinib as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol B)

NCT04439136
View directory record Official record
Conditions
Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
Interventions
Afatinib Dimaleate
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 7, 2026 · Synced Sep 23, 2026, 1:44 PM EDT
Completed Phase 4 Interventional Results available

Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients

NCT01129336
View directory record Official record
Conditions
First or Second Line HER2-negative Breast Cancer, Metastatic Disease Without Bone Metastasis
Interventions
Zoledronic acid, Standard Therapy
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
33
States / cities
Fayetteville, Arkansas • Jonesboro, Arkansas • Little Rock, Arkansas + 30 more
Source: ClinicalTrials.gov public record
Updated May 19, 2014 · Synced Sep 23, 2026, 1:44 PM EDT
Completed Phase 2 Interventional

Multicentre, Dose Finding, Ph II,CP-4055 in Comb. With Sorafenib - Patients With Metastatic Malignant Melanoma

NCT00498836
View directory record Official record
Conditions
Malignant Melanoma
Interventions
CP-4055, Sorafenib (Nexavar)
Drug
Lead sponsor
Clavis Pharma
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 11, 2013 · Synced Sep 23, 2026, 1:44 PM EDT
Completed Phase 1 Interventional Results available

Dose Escalation Study of MLN0128 in Participants With Advanced Malignancies

NCT01058707
View directory record Official record
Conditions
Advanced Solid Malignancies
Interventions
MLN0128
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2019
U.S. locations
14
States / cities
Scottsdale, Arizona • Los Angeles, California • Miami, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2020 · Synced Sep 23, 2026, 1:44 PM EDT
Withdrawn Phase 1 Interventional

Ex Vivo-Expanded HER2-Specific T Cells and Cyclophosphamide After Vaccine Therapy in Treating Patients With HER2-Positive Stage IV Breast Cancer

NCT01219907
View directory record Official record
Conditions
HER2-positive Breast Cancer, Male Breast Cancer, Stage IV Breast Cancer
Interventions
HER-2/neu peptide vaccine, cyclophosphamide, ex vivo-expanded HER2-specific T cells, laboratory biomarker analysis, flow cytometry, immunoenzyme technique
Biological · Drug · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 16, 2013 · Synced Sep 23, 2026, 1:44 PM EDT
Recruiting Phase 3 Interventional

Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis

NCT07325292
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Frexalimab, MRI contrast-enhancing preparations
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 60 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
23
States / cities
Cullman, Alabama • Homewood, Alabama • Phoenix, Arizona + 18 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Sep 23, 2026, 1:44 PM EDT
Enrolling by invitation Phase 3 Interventional

Study to Evaluate the Efficacy and Safety of Lerodalcibep in Children 6 to 17 Years, With Heterozygous FH

NCT07102511
View directory record Official record
Conditions
Familial Hypercholesterolemia - Heterozygous
Interventions
lerodalcibep 300 mg Monthly SC
Biological
Lead sponsor
LIB Therapeutics LLC
Industry
Eligibility
6 Years to 17 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Sep 23, 2026, 1:44 PM EDT
Completed Phase 2 Interventional

The Effect of Nasal Carbon Dioxide (CO2) in the Symptomatic Treatment of Seasonal Allergic Rhinitis

NCT00917111
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
Nasal CO2, Inactive Placebo Gas
Drug
Lead sponsor
Capnia, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Aug 14, 2012 · Synced Sep 23, 2026, 1:44 PM EDT
Recruiting Not applicable Interventional

Evaluation of Branch Endografts in the Treatment of Aortic Aneurysms

NCT01524211
View directory record Official record
Conditions
Thoracoabdominal Aortic Aneurysm, Aortic Arch Aneurysm
Interventions
Zenith® t-Branch, Terumo Arch Branch
Device
Lead sponsor
Baptist Health South Florida
Other
Eligibility
18 Years and older
Enrollment
235 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2032
U.S. locations
1
States / cities
Boca Raton, Florida
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Sep 23, 2026, 1:44 PM EDT
Completed Phase 4 Interventional Results available

Combined Mirtazapine and SSRI Treatment of PTSD: A Placebo-Controlled Trial

NCT01178671
View directory record Official record
Conditions
Posttraumatic Stress Disorder
Interventions
Mirtazapine, Sertraline, Sugar pill
Drug · Other
Lead sponsor
Research Foundation for Mental Hygiene, Inc.
Other
Eligibility
18 Years to 75 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 7, 2016 · Synced Sep 23, 2026, 1:44 PM EDT
Not listed Phase 2Phase 3 Interventional

Treatment of Corneal Abrasions With Topical Tetracaine

NCT02771392
View directory record Official record
Conditions
Corneal Abrasion
Interventions
Ophthalmic Tetracaine, Normal Saline
Drug · Other
Lead sponsor
New York Presbyterian Brooklyn Methodist Hospital
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated May 12, 2016 · Synced Sep 23, 2026, 1:44 PM EDT
Completed Not applicable Interventional Results available

CBT Enhanced With Social Cognitive Training

NCT03954392
View directory record Official record
Conditions
Depression
Interventions
Cognitive behavior therapy with social cognitive training (CBT+SCT), CBT-only
Behavioral
Lead sponsor
Vanderbilt University
Other
Eligibility
12 Years to 17 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
2
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 27, 2023 · Synced Sep 23, 2026, 1:44 PM EDT
Recruiting Phase 1 Interventional

Novel Cellular Therapy for the Treatment of Pain Associated With Chronic Pancreatitis

NCT05925036
View directory record Official record
Conditions
Chronic Pancreatitis, Chronic Pain
Interventions
Mesenchymal stem cells, Placebo
Drug · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Sep 23, 2026, 1:44 PM EDT